...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
AGORACOM NEWS FLASH

ATTENTION MEMBERS: 

Tonight, we're giving our website a serious makeover.  

So if you can't access the site for a bit, don't worry, we're just sprucing things up for an even smoother experience.  

In the event that you experience issues accessing the new site, please clear your browser's cookies and cache. 

See You On The Other Side!

Message: Re: Zenith ZEN-3694/Enzalutamid... mCRPC Phase 1b/2a Study Published
Reply New Message
Back To Forum List View
Icon president Zenith ZEN-3694/Enzalutamid... mCRPC Phase 1b/2a Study Published
5
BearDownAZ
Jul 28, 2020 10:52AM

Nice find Jonzobot. According to slide 26 of today's presentation, the newly listed trial (https://clinicaltrials.gov/ct2/show/NCT04471974) will be in addition to the planned "Randomized study of ZEN-3694 + enzalutamide in prostate cancer patients (early 2021)."

https://www.zenithepigenetics.com/upload/media_element/122/01/zenith-epigenetic-therapeutic-targets-2020-final.pdf

 

7 Recommendations
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply